Shikonin inhibits TNF-α production through suppressing PKC-NF-κB-dependent decrease of IL-10 in rheumatoid...

Area of Science:

• Pharmacology
• Immunology
• Rheumatology

Background:

• Rheumatoid arthritis (RA) is an inflammatory condition with complex mechanisms.
• Shikonin, a component of Lithospermum erythrorhizon, shows anti-inflammatory potential in RA.
• The precise mechanism of shikonin's action in RA remains to be elucidated.

Purpose of the Study:

• To investigate the mechanism by which shikonin exerts its anti-inflammatory effects on a lipopolysaccharide (LPS)-induced fibroblast-like synoviocyte (FLS) model of RA.
• To determine shikonin's impact on the expression of key inflammatory mediators, IL-10 and TNF-α, in FLSs.
• To identify the signaling pathways involved in shikonin's modulation of these mediators.

Main Methods:

• Establishment of an RA-like inflammation model using LPS-treated FLSs.
• Treatment of FLSs with varying concentrations of shikonin.
• Quantification of IL-10 and TNF-α mRNA and protein levels using qRT-PCR and ELISA.
• Analysis of signaling proteins, including those in the PKC-NF-κB pathway, via Western blotting.

Main Results:

• Shikonin reversed LPS-induced inhibition of IL-10 expression in FLSs by inactivating the PKC-NF-κB pathway.
• Shikonin significantly inhibited LPS-induced TNF-α expression in FLSs.
• The inhibitory effect of shikonin on TNF-α was dependent on IL-10, as demonstrated by neutralization studies and lack of response to protein synthesis inhibitors.

Conclusions:

• Shikonin suppresses LPS-induced TNF-α production in FLSs by mitigating a decrease in IL-10, mediated through the PKC-NF-κB pathway.
• These findings suggest that shikonin has potential therapeutic applications for rheumatoid arthritis.